{"id":6694,"date":"2022-11-14T11:15:00","date_gmt":"2022-11-14T11:15:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\/"},"modified":"2022-11-14T11:15:00","modified_gmt":"2022-11-14T11:15:00","slug":"nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\/","title":{"rendered":"Nanexa erh\u00e5ller godk\u00e4nnande att starta klinisk studie med NEX-20"},"content":{"rendered":"
\n

Nanexa AB (publ) meddelar idag att bolaget erh\u00e5llit godk\u00e4nnande fr\u00e5n L\u00e4kemedelsverket att starta klinisk pr\u00f6vning av l\u00e4kemedelskandidaten NEX-20, en l\u00e5ngtidsverkande formulering av lenalidomid, baserad p\u00e5 PharmaShell\u00ae-systemet, \u00e4mnad f\u00f6r underh\u00e5llsbehandling av cancerformen multipel myelom.<\/strong><\/p>\n<\/div>\n

\n

Studien \u00e4r en Fas 1-studie f\u00f6r att studera den farmakokinetiska profilen, s\u00e4kerhet och tolerabilitet av NEX-20, i stigande doser i friska frivilliga. Godk\u00e4nnande fr\u00e5n etikpr\u00f6vningsn\u00e4mnden har redan erh\u00e5llits och \u00f6vriga aktiviteter f\u00f6r att starta studien g\u00e5r enligt plan.<\/p>\n

\u201dGodk\u00e4nnandet \u00e4r en stor och viktig milstolpe f\u00f6r Nanexa d\u00e5 det \u00e4r den f\u00f6rsta kliniska studien i NEX-20-projektet. Det inneb\u00e4r att vi nu kan starta NEX-20-studien enligt tidplan och att vi tar v\u00e5rat andra l\u00e4kemedel baserat p\u00e5 PharmaShell in i klinik. Vi g\u00f6r oss nu redo inf\u00f6r start av studien och r\u00e4knar med att ha de f\u00f6rsta resultaten fr\u00e5n studien i f\u00f6rsta kvartalet n\u00e4sta \u00e5r\u201d, s\u00e4ger David Westberg, vd p\u00e5 Nanexa.<\/p>\n<\/div>\n

\n

F\u00f6r mer information kontakta:<\/strong><\/p>\n

\n

David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
Telefon: 0709-42 83 03
E-post:\u00a0david.westberg@nanexa.se<\/a>
www.nanexa.com<\/a><\/p>\n

Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n

\n

Om Nanexa AB (publ)<\/strong><\/p>\n

\n

Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland AstraZeneca.<\/p>\n

Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

Nanexa erh\u00e5ller godk\u00e4nnande att starta klinisk studie med NEX-20<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nanexa AB (publ) meddelar idag att bolaget erh\u00e5llit godk\u00e4nnande fr\u00e5n L\u00e4kemedelsverket att starta klinisk pr\u00f6vning av l\u00e4kemedelskandidaten NEX-20, en l\u00e5ngtidsverkande formulering av lenalidomid, baserad p\u00e5 PharmaShell\u00ae-systemet, \u00e4mnad f\u00f6r underh\u00e5llsbehandling av cancerformen multipel myelom.<\/p>\n","protected":false},"template":"","class_list":["post-6694","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa erh\u00e5ller godk\u00e4nnande att starta klinisk studie med NEX-20 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa erh\u00e5ller godk\u00e4nnande att starta klinisk studie med NEX-20 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB (publ) meddelar idag att bolaget erh\u00e5llit godk\u00e4nnande fr\u00e5n L\u00e4kemedelsverket att starta klinisk pr\u00f6vning av l\u00e4kemedelskandidaten NEX-20, en l\u00e5ngtidsverkande formulering av lenalidomid, baserad p\u00e5 PharmaShell\u00ae-systemet, \u00e4mnad f\u00f6r underh\u00e5llsbehandling av cancerformen multipel myelom.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\\\/\",\"name\":\"Nanexa erh\u00e5ller godk\u00e4nnande att starta klinisk studie med NEX-20 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2022-11-14T11:15:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa erh\u00e5ller godk\u00e4nnande att starta klinisk studie med NEX-20\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa erh\u00e5ller godk\u00e4nnande att starta klinisk studie med NEX-20 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa erh\u00e5ller godk\u00e4nnande att starta klinisk studie med NEX-20 - Nanexa AB","og_description":"Nanexa AB (publ) meddelar idag att bolaget erh\u00e5llit godk\u00e4nnande fr\u00e5n L\u00e4kemedelsverket att starta klinisk pr\u00f6vning av l\u00e4kemedelskandidaten NEX-20, en l\u00e5ngtidsverkande formulering av lenalidomid, baserad p\u00e5 PharmaShell\u00ae-systemet, \u00e4mnad f\u00f6r underh\u00e5llsbehandling av cancerformen multipel myelom.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\/","name":"Nanexa erh\u00e5ller godk\u00e4nnande att starta klinisk studie med NEX-20 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2022-11-14T11:15:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-erhaller-godkannande-att-starta-klinisk-studie-med-nex-20\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa erh\u00e5ller godk\u00e4nnande att starta klinisk studie med NEX-20"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}